Moreover, probiotic treatment downregulated the matrix metallopeptidase 9 (MMP9) and neurogenic locus notch homolog protein 1 (NOTCH 1) signaling pathways to prevent disease progression, indicating that probiotics could be used as adjuvant therapy for patients with T2DM and HCC [24]. Here, MMP9 is linked to hepatocellular carcinoma.